Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: Genetic background

International Journal of Neuropsychopharmacology

Volumn 14, Issue 6, 2011, Pages 796-833

  Piubelli, Chiara ^a   Vighini, Miriam ^a   Mathé, Aleksander A ^b   Domenici, Enrico ^a   Carboni, Lucia ^a  

^a GSK   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

2D electrophoresis; Escitalopram; hippocampus; maternal separation; prefrontal cortex; proteomics

Indexed keywords

ESCITALOPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; CYTOSKELETON; DEPRESSION; ENVIRONMENT; EXTRACTION; FORCED SWIMMING TEST; FRONTAL CORTEX; GENE INTERACTION; HIPPOCAMPUS; HUMAN; INJURY; MACROMOLECULE; MALE; MASS SPECTROMETRY; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTEOMICS; RAT; REGULATORY MECHANISM; TWO DIMENSIONAL ELECTROPHORESIS;

ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FRONTAL LOBE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; MALE; MATERNAL DEPRIVATION; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; NEURONS; PROTEOMICS; RATS; RATS, INBRED STRAINS; SEROTONIN UPTAKE INHIBITORS;

EID: 79958795202     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001318     Document Type: Article

References (80)

1. Anderson IM (2000). Selective serotonin reuptake inhibitors vs. tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36. (Pubitemid 30173208)
2. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, et al. (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 22, 343-396. (Pubitemid 351989984)
3. Arroll B, Macgillivray S, Ogston S, Reid I, et al. (2005). Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Annals of Family Medicine 3, 449-456. (Pubitemid 41512663)
4. Bao X, Pal R, Hascup KN, Wang Y, et al. (2009). Transgenic expression of Glud1 (glutamate dehydrogenase 1) in neurons: in vivo model of enhanced glutamate release, altered synaptic plasticity, and selective neuronal vulnerability. Journal of Neuroscience 29, 13929-13944.
5. Beasley CL, Pennington K, Behan A, Wait R, et al. (2006). Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 6, 3414-3425. (Pubitemid 43886157)
6. Berg D, Holzmann C, Riess O (2003). 14-3-3 proteins in the nervous system. Nature Reviews Neuroscience 4, 752-762. (Pubitemid 37280154)
7. Bianchi M, Fone KC, Shah AJ, Atkins AR, et al. (2009). Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. European Neuropsychopharmacology 19, 778-790.
8. Bianchi M, Hagan JJ, Heidbreder CA (2005). Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system? Current Drug Targets. CNS and Neurological Disorders 4, 597-611. (Pubitemid 41448385)
9. Blaveri E, Kelly F, Mallei A, Harris K, et al. (2010). Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours. PLoS ONE 5, e12596.
10. Bjørnebekk A, Mathé AA, Gruber SHM, Brené S (2008). Housing conditions modulate escitalopram effects on antidepressive-like behaviour and brain neurochemistry. International Journal of Neuropsychopharmacology 11, 1135-1147.
11. Bown C, Wang JF, MacQueen G, Young LT (2000). Increased temporal cortex ER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 22, 327-332. (Pubitemid 30089544)
12. Brown GW, Moran P (1994). Clinical and psychosocial origins of chronic depressive episodes. I: A community survey. British Journal of Psychiatry 165, 447-456. (Pubitemid 24305952)
13. Carboni L, Piubelli C, Pozzato C, Astner H, et al. (2006a). Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 137, 1237-1246. (Pubitemid 43133149)
14. Carboni L, Vighini M, Piubelli C, Castelletti L, et al. (2006b). Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists. European Neuropsychopharmacology 16, 521-537. (Pubitemid 44376555)
15. Cassimeris L (2002). The oncoprotein 18/stathmin family of microtubule destabilizers. Current Opinion in Cell Biology 14, 18-24. (Pubitemid 34131652)
16. Castren E (2004). Neurotrophic effects of antidepressant drugs. Current Opinion in Pharmacology 4, 58-64. (Pubitemid 38145839)
17. Cereseto M, Reines A, Ferrero A, Sifonios L, et al. (2006). Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus. European Journal of Neuroscience 24, 3354-3364. (Pubitemid 44952601)
18. Chen B, Wang JF, Young LT (2000). Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biological Psychiatry 48, 658-664.
19. Cumurcu BE, Ozyurt H, Etikan I, Demir S, et al. (2009). Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry and Clinical Neurosciences 63, 639-645.
20. Dennis G, Sherman BT, Hosack DA, Yang J, et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology 4, 3.
21. El HW, Powell JF, Surguladze SA (2009). Vulnerability to depression: what is the role of stress genes in generenvironment interaction? Psychological Medicine 39, 1407-1411.
22. El Khoury A, Gruber SH, Mork A, Mathe AA (2006). Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30, 535-540.
23. English JA, Dicker P, Focking M, Dunn MJ, et al. (2009). 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9, 3368-3382.
24. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry 53, 649-659. (Pubitemid 39658481)
25. Ferrero AJ, Cereseto M, Sifonios LL, Reines A, et al. (2007). Cytoskeleton of hippocampal neurons as a target for valproic acid in an experimental model of depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1419-1428. (Pubitemid 47302556)
26. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, et al. (2008). Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine 149, 734-750.
27. Ghaemi SN (2008). Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disorder 10, 957-968.
28. Guest PC, Knowles MR, Molon-Noblot S, Salim K, et al. (2004). Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling. Brain Research 1002, 1-10. (Pubitemid 38251573)
29. Hammen C (2005). Stress and depression. Annual Review of Clinical Psychology 1, 293-319. (Pubitemid 43843953)
30. Herbert B, Galvani M, Hamdan M, Olivieri E, et al. (2001). Reduction and alkylation of proteins in preparation of two-dimensional map analysis: why, when, and how? Electrophoresis 22, 2046-2057. (Pubitemid 32621934)
31. Horesh N, Klomek AB, Apter A (2008). Stressful life events and major depressive disorders. Psychiatry Research 160, 192-199.
32. Hunsucker SW, Solomon B, Gawryluk J, Geiger JD, et al. (2008). Assessment of post-mortem-induced changes to the mouse brain proteome. Journal of Neurochemistry 105, 725-737. (Pubitemid 351562727)
33. Hutchinson TH, Mahshid Y, Jonsson R, Bjorklund C, et al. (2008). Proteomic analysis of phospholipidosis in citalopram treated U937 cells - support for the cholesterol biosynthesis hypothesis. Toxicology in vitro: an international journal published in association with BIBRA 22, 1198-1204.
34. Ishikawa S, Taira T, Niki T, Takahashi-Niki K, et al. (2009). Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1. Journal of Biological Chemistry 284, 28832-28844.
35. Kamada H, Saito T, Hatta S, Toki S, et al. (1999). Alterations of tubulin function caused by chronic antidepressant treatment in rat brain. Cellular and Molecular Neurobiology 19, 109-117. (Pubitemid 29102099)
36. Katayama T, Hattori T, Yamada K, Matsuzaki S, et al. (2009). Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms? Pharmacogenomics 10, 1967-1978.
37. Keers R, Uher R, Huezo-Diaz P, Smith R, et al. (2010). Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal. Published online: 9 March 2010. doi: 10.1038/tpj.2010.14.
38. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, et al. (2003). Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Report: Communications in Free Radical Research 8, 365-370. (Pubitemid 38128544)
39. Law AJ, Harrison PJ (2003). The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. Journal of Psychiatric Research 37, 487-499. (Pubitemid 37238942)
40. Leonard BE (2001). The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25, 767-780. (Pubitemid 32374966)
41. Malberg JE, Blendy JA (2005). Antidepressant action: to the nucleus and beyond. Trends in Pharmacological Sciences 26, 631-638. (Pubitemid 41636308)
42. Marais L, Hattingh SM, Stein DJ, Daniels WM (2009). A proteomic analysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment. Metabolic Brain Disease 24, 569-586.
43. Mason BL, Pariante CM (2006). The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News & Perspectives 19, 603-608. (Pubitemid 46813847)
44. Mathè AA, Stenfors C, Brodin E, Theodorsson E (1990). Neuropeptides in brain: effects of microwave irradiation and decapitation. Life Sciences 46, 287-293. (Pubitemid 20038361)
45. McHugh PC, Rogers GR, Loudon B, Glubb DM, et al. (2008). Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. Journal of Neuroscience Research 86, 306-316. (Pubitemid 351196736)
46. Miguel-Hidalgo JJ, Dubey P, Shao Q, Stockmeier C, et al. (2005). Unchanged packing density but altered size of neurofilament immunoreactive neurons in the prefrontal cortex in schizophrenia and major depression. Schizophrenia Research 76, 159-171. (Pubitemid 40804763)
47. Montgomery SA (2006). Why do we need new and better antidepressants? International Clinical Psychopharmacology 21 (Suppl. 1), S1-S10. (Pubitemid 43740326)
48. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22, 323-329. (Pubitemid 47530836)
49. Moretti A, Gorini A, Villa RF (2003). Affective disorders, antidepressant drugs and brain metabolism. Molecular Psychiatry 8, 773-785. (Pubitemid 37100711)
50. Murdoch D, Keam SJ (2005). Escitalopram: a review of its use in the management of major depressive disorder. Drugs 65, 2379-2404. (Pubitemid 41573609)
51. Nakatani N, Ohnishi T, Iwamoto K, Watanabe A, et al. (2007). Expression analysis of actin-related genes as an underlying mechanism for mood disorders. Biochemical and Biophysical Research Communications 352, 780-786. (Pubitemid 44883370)
52. Ng F, Berk M, Dean O, Bush AI (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 11, 851-876.
53. Overstreet DH, Friedman E, Mathe AA, Yadid G (2005). The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neuroscience and Biobehavioral Reviews 29, 739-759. (Pubitemid 40762598)
54. Palotas M, Palotas A, Puskas LG, Kitajka K, et al. (2004). Gene expression profile analysis of the rat cortex following treatment with imipramine and citalopram. International Journal of Neuropsychopharmacology 7, 401-413. (Pubitemid 39648070)
55. Papakostas GI, Thase ME, Fava M, Nelson JC, et al. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62, 1217-1227. (Pubitemid 350060895)
56. Parker KC, Walsh RJ, Salajegheh M, Amato AA, et al. (2009). Characterization of human skeletal muscle biopsy samples using shotgun proteomics. Journal of Proteome Research 8, 3265-3277.
57. Pearson KA, Stephen A, Beck SG, Valentino RJ (2006). Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats. Neuropsychopharmacology 31, 2449-2461. (Pubitemid 44607063)
58. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999). Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567. (Pubitemid 30007252)
59. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109. (Pubitemid 350191319)
60. Piubelli C, Vighini M, Mathé AA, Domenici E, Carboni L (2010). Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. International Journal of Neuropsychopharmacology. doi: 10.1017/ S1461145710001306.
61. Porsolt RD, Le Pichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730-732. (Pubitemid 8073804)
62. Reines A, Cereseto M, Ferrero A, Bonavita C, et al. (2004). Neuronal cytoskeletal alterations in an experimental model of depression. Neuroscience 129, 529-538. (Pubitemid 39487107)
63. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA,et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905-1917. (Pubitemid 44807782)
64. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, et al. (2003). Escitalopram, the S enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berlin) 167, 353-362. (Pubitemid 36754236)
65. Schloss P, Henn FA (2004). New insights into the mechanisms of antidepressant therapy. Pharmacology & Therapeutics 102, 47-60. (Pubitemid 38429985)
66. Schubert V, Dotti CG (2007). Transmitting on actin: synaptic control of dendritic architecture. Journal of Cell Science 120, 205-212.
67. Shao L, Sun X, Xu L, Young LT, et al. (2006). Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sciences 78, 1317-1323. (Pubitemid 43199952)
68. Shumyatsky GP, Malleret G, Shin RM, Takizawa S, et al. (2005). Stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell 123, 697-709. (Pubitemid 41608470)
69. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years on. Trends in Pharmacological Sciences 30, 563-569.
70. Sun L, Bittner MA, Holz RW (2003). Rim, a component of the presynaptic active zone and modulator of exocytosis, binds 14-3-3 through its N terminus. Journal of Biological Chemistry 278, 38301-38309. (Pubitemid 37221721)
71. Theodorsson E, Stenfors C, Mathé AA (1990). Microwave irradiation increases recovery of neuropeptides from brain tissues. Peptides 11, 1191-1197.
72. Tsankova NM, Berton O, Renthal W, Kumar A, et al. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience 9, 519-525.
73. Uher R (2008). The implications of gene-environment interactions in depression: will cause inform cure? Molecular Psychiatry 13, 1070-1078.
74. Uher R, Perroud N, Ng MY, Hauser J, et al. (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry 167, 555-564.
75. Vaidya VA, Terwilliger RZ, Duman RS (2000). Alterations in heavy and light neurofilament proteins in hippocampus following chronic ECS administration. Synapse 35, 137-143. (Pubitemid 30036190)
76. Warner-Schmidt JL, Duman RS (2006). Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16, 239-249.
77. Wong ML, O'Kirwan F, Hannestad JP, Irizarry KJ, et al. (2004). St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Molecular Psychiatry 9, 237-251. (Pubitemid 38496714)
78. Yadid G, Nakash R, Deri I, Tamar G, et al. (2000). Elucidation of the neurobiology of depression: insights from a novel genetic animal model. Progress in Neurobiology 62, 353-378. (Pubitemid 30336473)
79. Yang C, Wang G, Wang H, Liu Z, et al. (2009). Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. Behavioral Brain Research 205, 518-524.
80. Yudkoff M, Nissim I, Nelson D, Lin ZP, et al. (1991). Glutamate dehydrogenase reaction as a source of glutamic acid in synaptosomes. Journal of Neurochemistry 57, 153-160.